Literature DB >> 25823791

Randomized Trial of Studer Pouch versus T-Pouch Orthotopic Ileal Neobladder in Patients with Bladder Cancer.

Eila C Skinner1, Adrian S Fairey2, Susan Groshen3, Siamak Daneshmand3, Jie Cai3, Gus Miranda3, Donald G Skinner3.   

Abstract

PURPOSE: The need to prevent reflux in the construction of an orthotopic ileal neobladder is controversial. We designed the USC-STAR trial to determine whether the T-pouch neobladder that included an antireflux mechanism was superior to the Studer pouch in patients with bladder cancer undergoing radical cystectomy.
MATERIALS AND METHODS: This single center, randomized, controlled trial recruited patients with clinically nonmetastatic bladder cancer scheduled to undergo radical cystectomy with neobladder. Eligible patients were randomly assigned to undergo T-pouch or Studer ileal orthotopic neobladder. Treatment assignment was not masked. The primary end point was change in renal function from baseline to 3 years. The CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation was used to calculate the estimated glomerular filtration rate.
RESULTS: Between February 2002 and November 2009, 237 patients were randomly assigned to T-pouch ileal orthotopic neobladder and 247 to Studer ileal orthotopic neobladder. Baseline characteristics did not differ between the groups. Between baseline and 3 years the estimated glomerular filtration rate decreased by 6.4 ml/minute/1.73 m(2) in the Studer group and 6.6 ml/minute/1.73 m(2) in the T-pouch group (p=0.35). Multivariable analysis showed that type of ileal orthotopic neobladder was not independently associated with 3-year renal function (p=0.63). However, baseline estimated glomerular filtration rate, age and urinary tract obstruction were independently associated with 3-year decline in renal function. Cumulative risk of urinary tract infection and overall late complications were not different between the groups, but the T-pouch was associated with an increased risk of secondary diversion related surgeries.
CONCLUSIONS: T-pouch ileal orthotopic neobladder with an antireflux mechanism did not prevent a moderate reduction in renal function observed at 3 years compared to the Studer pouch, but did result in an increase in diversion related secondary surgical procedures.
Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cystectomy; urinary diversion

Mesh:

Year:  2015        PMID: 25823791     DOI: 10.1016/j.juro.2015.03.101

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

Review 1.  Updates on Robotic Intracorporeal Urinary Diversions.

Authors:  Shawn Dason; Alvin C Goh
Journal:  Curr Urol Rep       Date:  2018-03-15       Impact factor: 3.092

Review 2.  Complications of Radical Cystectomy and Orthotopic Reconstruction.

Authors:  Wei Shen Tan; Benjamin W Lamb; John D Kelly
Journal:  Adv Urol       Date:  2015-11-30

3.  Laparoscopic radical cystectomy with pelvic lymph node dissection and ileal orthotopic neobladder by a total extraperitoneal approach: Our initial technique and short-term outcomes.

Authors:  Guanqun Zhu; Zongliang Zhang; Kai Zhao; Xinbao Yin; Yulian Zhang; Zhenlin Wang; Chen Li; Yuanming Sui; Xueyu Li; Han Yang; Nianzeng Xing; Ke Wang
Journal:  Investig Clin Urol       Date:  2022-09

4.  Febrile Urinary Tract Infection after Radical Cystectomy and Ileal Neobladder in Patients with Bladder Cancer.

Authors:  Kwang Hyun Kim; Hyun Suk Yoon; Hana Yoon; Woo Sik Chung; Bong Suk Sim; Dong Hyeon Lee
Journal:  J Korean Med Sci       Date:  2016-05-18       Impact factor: 2.153

Review 5.  Advances in bladder substitution and creation of neobladders in children.

Authors:  Jennifer E Reifsnyder; Moneer K Hanna
Journal:  F1000Res       Date:  2019-11-26

6.  Ureteroenteric strictures: a single center experience comparing Bricker versus Wallace ureteroileal anastomosis in patients after urinary diversion for bladder cancer.

Authors:  Frank Christoph; Franziska Herrmann; Peter Werthemann; Thomas Janik; Martin Schostak; Christian Klopf; Steffen Weikert
Journal:  BMC Urol       Date:  2019-10-24       Impact factor: 2.264

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.